Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk Nicholas Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits‐Filho, Richard K. S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimı́r Tesař, Hernán Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard A. Lafayette
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
ConclusionsAtacicept slowed and stabilized the decline in the eGFR as compared with placebo.
ConclusionsAmong patients with IgA nephropathy, treatment with sibeprenlimab stabilized the eGFR slope over 24 months, a finding consistent with a reduced risk of kidney-function decline.
Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki and 22 more — New England Journal of Medicine
No mortality occurred at 5000 mg/kg, giving an LD50 above that limit; clinical signs, body weight, and rectal temperature showed no dose-related change.
N. N. Fadilah, S. R. Nur Endah, S. A. Sumiwi and 2 more — bioRxiv
Conclusions and Relevance For participants with newly diagnosed or relapsing EGPA, rituximab was not superior to azathioprine for improving the duration of total remission during 28 months while taking prednisone at 7.5 mg/d or less.
Xavier Puéchal, G. Pugnet, Benjamin Thoreau and 57 more — JAMA
BCI accuracy increased across training in four of five patients and was accompanied by patient-specific longitudinal changes in local spectral activity and functional connectivity.
C. Bousfiha, C. Gabot, D. Baili and 10 more — medRxiv
With the goal to develop better PDE4 inhibitors for the treatment of plaque psoriasis, two novel drug candidates were designed with computational studies, and observed to have better ADMET properties compared to Roflumilast.